STAT News

NOVEMBER 4, 2022

A man with muscular dystrophy who was first in line to receive an experimental gene editing therapy tailor made to treat the cause of his rare form of the disease has died. The clinical trial was to be the first time anyone got a gene editing therapy for muscular dystrophy.

Gene Editing 105

Gene Editing Gene Gene Therapy Scientist 105

pharmaphorum

JUNE 28, 2021

The reductions matched the efficacy of current therapies for ATTR amyloidosis that require chronic dosing such as Alnylam’s Onpattro (patisiran) and Ionis/Akcea’s Tegsedi (inotersen) – both gene-silencing agents which can cost around $450,000 a year. — Eric Topol (@EricTopol) June 26, 2021.

In-Vivo 105

In-Vivo Gene Editing Trials Drugs 105

The Pharma Data

MARCH 7, 2022

The new technique controls gene activity without altering the DNA sequence of the genome by targeting chemical modifications that help package genes in our chromosomes and regulate their activity. These methyl groups must be refreshed so if PRC2 is blocked the genes it has silenced. it can be reawakened.

Protein 52

Protein Gene Genome Genomics 52

XTalks

AUGUST 2, 2023

2) Paxlovid (nirmatrelvir/ritonavir) Paxlovid is a dual-packaged oral medication for the treatment of COVID-19. a month for either 150 mg or 300 mg dose strength packages, and $3,462.13 for the 75 mg dose strength package in January 2023, according to the manufacturer. for a 2-pen package (0.6 for the 3-pen package (1.8

Sales 98

Sales Manufacturing FDA Approval Life Science 98

XTalks

FEBRUARY 10, 2023

Integrate clinical workflow considerations in the packaging and handling design of the investigational product (IP). Medpace has IP experience with both autologous and allogeneic cellular products, ex vivo and in vivo gene transfer, and a number of different gene-editing mechanisms.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Gene Therapy 52

XTalks

FEBRUARY 11, 2021

After several such Nobel Prize snubs for female scientists, 2020 saw the Nobel Prize in Chemistry go to a female scientist duo for the first time for their revolutionary discovery of the CRISPR-Cas9 gene editing system. As a Black female scientist, her legacy is one that will continue to inspire generations of Black women to come.

Genetics 119

Genetics DNA Genome Genomics 119

Roots Analysis

JANUARY 27, 2025

Throughout her dynamic tenure, Dakshita has made significant strides to evaluate emerging trends and technologies within the pharmaceutical industry, contributing critically to numerous comprehensive research reports that provide in-dept views on topics such as gene-editing, subcutaneous biologics and cell therapy packaging.

Marketing 40

Marketing Drug Delivery Development Protein 40